Stephen Deitsch
Known title: DirectorCIK: 0001704288
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Auddia Cancels Oct 7 Meeting, Merger Support Stays Strong. Auddia has postponed its October 7 shareholder meeting that was set to vote on a merger with Thramann Holdings. The company says support for the merger remains strong and has set a new record date, with the meeting to be rescheduled. In pre‑market trading, the stock moved along with other IT names, trading near its 52‑week low and around the $1.02 support level.
Transaction History
| ACON | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 | View on chart |
| AUUD | ▼ Sell | Tax Withholding | 275 | $140 | 2/16/2025 | View on chart |
| AUUD | ▲ Buy | Option Exercise | 915 | — | 2/16/2025 | View on chart |
| AUUD | ▲ Buy | Option Exercise | 22,875 | — | 2/16/2024 | View on chart |
| AUUD | ▼ Sell | Tax Withholding | 6,863 | $2K | 2/16/2024 | View on chart |
| AUUD | ▲ Buy | Option Exercise | 22,875 | — | 2/16/2023 | View on chart |
| AUUD | ▼ Sell | Tax Withholding | 6,863 | $7K | 2/16/2023 | View on chart |
| AUUD | ▲ Buy | Option Exercise | 22,875 | — | 2/16/2022 | View on chart |
| AUUD | ▼ Sell | Tax Withholding | 6,863 | $12K | 2/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
ACON Adds NYU Langone Health to CLARITY Trial Network
Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.
ACON Adds NYU Langone Health to CLARITY Trial Network. Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.